StemCell Therapy

stem cells | 3 Reasons to Donate Umbilical Cord Blood to Public Bank
http://www.cordbloodrecommendation.com Moreover, it is not difficult to find a family member that can provide a match. So, really, how much does it cost?Well, it all depends on which bank you go for. The red blood cells and plasma will be separated out. Basically, children who have the same parents have the same genes. Make sure that the facility is accredited and is recognized by the authorities. Amongst all, banking the baby #39;s cord blood is one major decision that parents need to make. 4. Public Cord Blood Banking services are free. If you have hepatitis B or C you do not qualify to donate. Hence, blood transplant can cover a wider range of recipients. ""Cord Blood also called ""placental blood,"" is the blood that remains in the umbilical cord and placenta after the cord has been cut following the birth of the baby. David #39;s recovery has given hope to his twin brother, Christopher who is still waiting for a bone marrow or cord blood match. 1 - Cord Blood Banks Are NewThe science behind them isn #39;t particularly complex but as with any new business model not every company that is involved in it will last. The cost of private blood bank ranges from $900 - $2000, depending on the bank you choose, along with the initial fee, you will need to pay an annual storage fee of $125. These cells will help repair lungs after injury or disease. The former has an advantage that there is no risk of graft vs. By preserving your baby #39;s cord blood, you are actually increasing yourFrom:Implantes DentalesViews:0 0ratingsTime:01:18More inScience Technology

Here is the original post:
stem cells | 3 Reasons to Donate Umbilical Cord Blood to Public Bank - Video

umbilical cord | How Much Does Banking Cord Blood Cost?
http://www.cordbloodrecommendation.com To get these stem cells, your doctor will draw blood from the umbilical cord at the time of your baby #39;s birth. Donated cord blood is available for public use and research, and has proven to save many lives. Preserving this blood can be very useful not only for the baby, but also for her siblings and other members of the family, especially when it comes to the treatment of certain medical conditions and diseases, such as diabetes, Parkinson #39;s, multiple sclerosis and leukemia. This is an opportunity for you to bank your child #39;s umbilical cord blood. The surface of the umbilical cord is disinfected and a vein is punctured. Amongst all, banking the baby #39;s cord blood is one major decision that parents need to make. In order to keep it sterilized, it is then cryogenically stored either in a public or private bank until it is needed for transplant. The scientific community is optimistically hopeful that these cells will be able to allow regeneration of organs in the human body. The umbilical cord is a cord that connects the fetus to the mother #39;s body and this is where all the essential nutrients and blood travel through to the fetus. The stem cells from your baby #39;s blood may be capable to cure definite diseases or circumstances of a blood relation or relatives. It can be taken using either a syringe to remove the blood (syringe method) from the vein or by allowing it to drain by gravity into a collection bag (bag method). They do not charge any ...From:LosHotelesEnBogotaViews:0 0ratingsTime:01:18More inScience Technology

See the original post:
umbilical cord | How Much Does Banking Cord Blood Cost? - Video

stem cells | Cord Blood - Why So Important?
http://www.cordbloodrecommendation.com Private banks are often sought for families as a type of insurance, in the event of future illness, accident or medical emergency. The blood that remains when the umbilical cord is separated from the newborn infant contains vital components of blood and is a necessity when it comes to treating fatal diseases of the human blood. It may not occur immediately after the transplant. Not any more, as such blood has been found to be a very important and rich source of stem cells, and stem cells is mankind #39;s latest hope in its battle against age-old fatal diseases. Lately, it has become increasingly clear that the cord , placenta as well as the surrounding tissue of the umbilical cord are an additional source of stem cells. The slow engraftment due to the restricted amount of hematopoietic stem cell present in one unit of umbilical blood can cause high peritransplant death and restrict the success of umbilical cord blood transplant, particularly in adults. This conversion of cells offers physicians with a technique to treat leukemia and some hereditary illnesses. Public Cord Blood Banking services are free. One of the final pros would be the benefit of the entire family. With the use of cells, the body can be induced to produce healthy blood cells which can then fight off the cancer. Brother, sister, mom or dad. It is indicated by the decline of muscle function, motor skills, and speech patterns. The baby suffers no debit or hurt through this ...From:fivespanishViews:0 0ratingsTime:01:18More inScience Technology

Continued here:
stem cells | Cord Blood - Why So Important? - Video

stem cell banking | Cord Blood
http://www.cordbloodrecommendation.com ""There are several advantages to cord blood banking. Advantages Of Cord Blood Banking1. 2. There are many diseases that can be treated with stem cells, so if your child ever needs stem cells later in his/her life, you will not have to look for a new donor. Placental and cord blood banking may become even more valuable in the future with exciting research under way to find new medical uses in areas such as: diabetes, heart disease, liver disease, muscular dystrophy, Alzheimer #39;s disease, Parkinson #39;s disease, stroke, and even spinal cord injury. However, in the event that you actually need the cord blood, I am sure there is no price too high for a parent to be willing to pay. Sometimes people cannot use their own because it still may carry a genetic disorder. Thomas, who will not have access to a close relative #39;s stem cells. It is always wise to preserve this waste blood of the baby which is otherwise thrown away. In this case, it will be better to bank the cord blood for possible future need. Usually, cord blood stem cell banking comes with a payment package that sum up fees for enrollment information, collection kits, courier charges, banks laboratory, sample typing, processing, storing and maintenance of the cord blood units. In the future, researchers might be able to examine cord blood from babies with lung diseases such as cystic fibrosis and develop better treatments. Nowadays, there is a bank which provides you a service for storing ...From:Aldana LuisViews:0 0ratingsTime:01:18More inScience Technology

See original here:
stem cell banking | Cord Blood - Video

umbilical cord | Cord Blood To Cure Thalassemia And Many More Diseases
http://www.cordbloodrecommendation.com In 2006, Shelia Gannon was close to the end of a losing battle against acute lymphoblastic leukemia (ALL), a form of cancer that causes abnormal blood formation and a shortage of red and normal white blood cells and platelets. . Now in a few words, stem cells are simply the beginning of all potential: a stem cell can be induced to form organs of a specific cell type, such as liver or kidneys, with the help of chemical and physical cues. Even if for some reason your donation isn #39;t eligible for transplant purposes, it can still be used for research. Placental and cord blood banking may become even more valuable in the future with exciting research under way to find new medical uses in areas such as: diabetes, heart disease, liver disease, muscular dystrophy, Alzheimer #39;s disease, Parkinson #39;s disease, stroke, and even spinal cord injury. Myth 2 : if your family doesn #39;t have a record of cancer, your baby or sibling won #39;t ever require stem cells. This is true especially in children. Thomas, who will not have access to a close relative #39;s stem cells. It is always wise to preserve this waste blood of the baby which is otherwise thrown away. Cord blood storage might become a new trend very soon. Usually, cord blood stem cell banking comes with a payment package that sum up fees for enrollment information, collection kits, courier charges, banks laboratory, sample typing, processing, storing and maintenance of the cord blood units. Around 40 to 150ml ...From:HotelesEnBuenosAiresViews:0 0ratingsTime:01:18More inScience Technology

See the rest here:
umbilical cord | Cord Blood To Cure Thalassemia And Many More Diseases - Video

cord blood banking | 3 Reasons to Donate Umbilical Cord Blood to Public Bank
http://www.cordbloodrecommendation.com Cord blood will be the right answer for some diseases. These regulations set up the legal foundation and provide validation to the significance of the storage. Once you catalog with a cord blood cache, they forward you a kit, containing all the crucial gear for collecting cord blood, along with instructions for the presence doctor, imparter or attention employees. It may cost you around $700 for collection, processing, and storage in Australia, and about $16000 to get a suitable sample from the ACBB to be used in transplant. Doctors injected the stem cells directly into the damaged portion of her spine. Doctors search the NMDP Registry of adult marrow or peripheral blood cell donors and cbus to find a suitable HLA match for their patients who need a transplant. Here the stem cell #39;s are removed from the blood and stored particularly for the later use of your family. These HPC cells are injected to them in order to restore their blood supply with newer, healthy cells. These storage facilities are approved by the FDA and deemed a safe place to keep it at the proper temperature and contamination free. ""When it comes to having a new baby--whether the child is your family #39;s firstborn or tenth--there are many decisions that must be made involving their birth and health care. ""It is an establishment that stores umbilical cord blood for future use. Current data reflect that those that have been stored for fifteen years have the same ability as ...From:hotelesenMelgarViews:0 0ratingsTime:01:18More inScience Technology

Go here to read the rest:
cord blood banking | 3 Reasons to Donate Umbilical Cord Blood to Public Bank - Video

cord blood bank | Compare Cord Blood Banks
http://www.cordbloodrecommendation.com Sprague underwent the treatment in November 1997, and has now been cancer free for over nine years. Hence, these types of cells are the building blocks of the human body, repairing what ever is deficient in the human body. It is basically the cancer of the blood and marrow, and leads to a reduction of white blood cells in the body. If you plan on donating the umbilical blood the doctor collecting the blood will not charge for their service. The second is a private bank. The average fee is around twenty five hundred dollars. Parents, especially mothers to be must be given counseling at the hospitals, so that they realize how important it is for the baby. But, much study and research needs to be done to understand these cells. The stem cells are already present in the cord blood bank, so, are easily available in case of the transplant. As a pro, maybe stem cells will be even more of a powerful medicine making the banking of the blood even more important. The lesser your cord blood unit has to travel before preservation, the better. You however, have the option of donating or giving for some consideration the blood to a needy patient a few years down the line when you are sure of your baby #39;s health. This is attributed to the fact that the stem cells found in the umbilical blood are a lot younger. Probability varies from 1/1500 up to 1/200000. There is also the possibility that they can be used in regenerative treatments for brain injuries ...From:2angelasmithViews:0 0ratingsTime:01:18More inScience Technology

Continue reading here:
cord blood bank | Compare Cord Blood Banks - Video

cord blood center | Cord Blood Donation - Donate Cord Blood Cells For the Well-Being Of Your Family
http://www.cordbloodrecommendation.com Her doctors suggested the possibility of a cord blood stem cell transplant. Doctors have little experience in cord blood stem cell transplantation. What is flexing Blood saving?Flex blood caching is a breakthrough in blood caching. The blood is generally kept in storage until the donor (the newborn baby) is 21 years old. ""When it comes to cord blood banking cost, it #39;s the first year that dissuades most that do not pursue it. There is also a yearly fee. With just one opportunity to collect it, whether you should store your child #39;s umbilical cord blood at a private cord bank or donate it for public use is ultimately a personal decision that only you can make. At the end of the day, it is your decision. How to do cord blood banking?All you need to do is store your newborn baby #39;s umbilical cord and placenta during delivery with some medical aid. For instance, they are not comfortable with the results. ""Umbilical cord blood contains blood-forming cells that can be used to treat life-threatening diseases and conditions. The slow engraftment because of the limited number of hematopoietic stem cells available in a single unit of umbilical cord blood may contribute to high peritransplant mortality and limit the success of umbilical cord blood transplant especially in adult patients. ""The decision for cord blood collection has to be made well in advance of delivery. For more information, please visit the company #39;s website.From:luisantafeViews:1 0ratingsTime:01:18More inScience Technology

Originally posted here:
cord blood center | Cord Blood Donation - Donate Cord Blood Cells For the Well-Being Of Your Family - Video

Science#1 stem cells
Firdt episode of science, today we look st stem cells and grow a hand :)From:glockerstimeViews:2 1ratingsTime:06:29More inPeople Blogs

See the original post here:
Science#1 stem cells - Video

Stem Cells: Revolutionizing the Treatments of Human Diseases
Stem Cells: Revolutionizing the Treatments of Human Diseases, recorded November 7, 2012. Topics Covered: Stem Cells, Developmental Biology, Research For more information and access to courses, lectures, and teaching material, please visit the official UC Irvine OpenCourseWare website at: ocw.uci.eduFrom:UCIrvineOCWViews:2 0ratingsTime:47:25More inEducation

See the original post:
Stem Cells: Revolutionizing the Treatments of Human Diseases - Video

What Are Stem Cells and their Benefits?
http://www.lami9cares.comFrom:Lami9CanadaViews:0 0ratingsTime:06:15More inPeople Blogs

Read the original:
What Are Stem Cells and their Benefits? - Video

Adult Stem Cells Not Embryonic Repair and Renew your Body
http://www.stemcelldetails4u.blogspot.inFrom:Nagarajan GViews:0 0ratingsTime:02:09More inScience Technology

View original post here:
Adult Stem Cells Not Embryonic Repair and Renew your Body - Video

Pluristem Therapeutics Inc. (PSTI) said a second of the three patients given the companys experimental stem cells has died after Pluristem touted the treatments as life-saving.

Pluristem shares soared after the Haifa, Israel-based company issued news releases in May, August and September announcing the treatments. Pluristem raised $34 million in a share sale in September without announcing that the first of those patients, a 7-year-old girl with a bone-marrow disease, had died. The company issued a press release today acknowledging the death of a second patient, though it wouldnt say when the death occurred.

Pluristem sank the most in 21 months in Nasdaq Stock Market trading yesterday after Bloomberg News reported Pluristem hadnt disclosed the girls death before the share sale. The company said today it wasnt aware of her death at the time of the offering.

The pediatric patient referred to in the Bloomberg article survived for six months, another patient survived for four months, and the third is still alive, the company said in todays statement. Pluristem believes that these results exceeded longevity expectations. The unfortunate deaths of the patients do not diminish these results.

The May 9 announcement of the girls treatment was headlined, Compassionate Use of Pluristems PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure. On Aug. 6, the company said the cells had been administered to a 54-year-old woman with cancer suffering from bone-marrow failure. Pluristem quoted her doctor in the news release describing her subsequent recovery as a medical miracle. On Sept. 9, the company said a 45-year-old man with leukemia had received a life-saving treatment with the cells.

A spokeswoman for Pluristem declined to say today whether it was the 54-year-old woman or the 45-year-old man who had died, or provide any details about the death.

Pluristems announcements helped lift the stock from its 2012 low of $2.02 in March to an intraday high of $5 on Aug. 17.

Such press releases risk misleading investors by creating overly optimistic account of scientific research, Leigh Turner, an associate professor at the University of Minnesota Center for Bioethics, said in a blog posting yesterday. More importantly, press releases describing miracles and life-saving cures are harmful because they give seriously ill individuals an unrealistic account of effectiveness of experimental stem cell interventions.

The stock plunged after the company announced on Sept. 12 that it planned to sell shares to raise money for research expenses. Pluristem completed the sale Sept. 19. The girl died Sept. 12, a company spokeswoman said last month.

Pluristem didnt announce the girls death because it stopped following her progress after she left the hospital, Chief Executive Officer Zami Aberman said in an interview last month. She had been critically ill, and her death was unrelated to the stem-cell treatment, the company said in todays statement. Pluristem learned of her death at the discretion of her family and physician in her home country of Romania after the stock sale, the company said.

Read more:
Pluristem: Second Patient With ‘Life-Saving’ Cells Died

Every week in his clinic at the University of Michigan, neurologist Joseph Corey, M.D., Ph.D., treats patients whose nerves are dying or shrinking due to disease or injury. He sees the pain, the loss of ability and the other effects that nerve-destroying conditions cause - and wishes he could give patients more effective treatments than what's available, or regenerate their nerves.

Then he heads to his research lab at the VA Ann Arbor Healthcare System, where his team is working toward that exact goal.

In new research published in several recent papers, Corey and his colleagues from the U-M Medical School, VAAAHS and the University of California, San Francisco report success in developing polymer nanofiber technologies for understanding how nerves form, why they don't reconnect after injury, and what can be done to prevent or slow damage.

Using polymer nanofibers thinner than human hairs as scaffolds, researchers coaxed a particular type of brain cell to wrap around nanofibers that mimic the shape and size of nerves found in the body.

They've even managed to encourage the process of myelination - the formation of a protective coating that guards larger nerve fibers from damage. They began to see multiple concentric layers of the protective substance called myelin start to form, just as they do in the body. Together with the laboratory team of their collaborator Jonah Chan at UCSF, the authors reported the findings in Nature Methods.

The research involves oligodendrocytes, which are the supporting actors to neurons - the "stars" of the central nervous system. Without oligodendrocytes, central nervous system neurons can't effectively transmit the electrical signals that control everything from muscle movement to brain function.

Oligodendrocytes are the type of cells typically affected by multiple sclerosis, and loss of myelin is a hallmark of that debilitating disease.

The researchers have also determined the optimum diameter for the nanofibers to support this process - giving important new clues to answer the question of why some nerves are myelinated and some aren't.

While they haven't yet created fully functioning "nerves in a dish," the researchers believe their work offers a new way to study nerves and test treatment possibilities. Corey, an assistant professor of neurology and biomedical engineering at the U-M Medical School and researcher in the VA Geriatrics Research, Education and Clinical Center, explains that the thin fibers are crucial for the success of the work.

"If it's about the same length and diameter as a neuron, the nerve cells follow it and their shape and location conform to it," he says. "Essentially, these fibers are the same size as a neuron."

Original post:
Stem cells and nanofibers stimulating nerve research

EASTERN SHORE, Md. (WJZ) The miracle of stem cells changes the life of a little boy from the Eastern Shore.

Adam May has the amazing story of a mother and the choice she made moments after her son was born.

Xander McKinley was a beautiful babybut challenging. The newborn didnt eat or sleep well, and by two-years-old, he couldnt walk or even crawl.

Something just wasnt right, said Xanders mother, Jennifer McKinley.

Jennifer McKinley got the news every parent fears. Xander had cerebral palsya brain condition that slows motor functions.

Adam: Did you ever fear he would never have a normal life? Jennifer: We thought he wasnt going to be able to walk. It was heart-wrenching, that we knew this was permanent.

Turns out, it wasnt permanent. That young boy frustrated by immobility can now stand on his own, and even take a few stepsafter a groundbreaking experimental stem cell transfusion.

Adam: Arent you walking better now? Xander: Yeah. Adam: How good does that feel? Xander: Great!

The 6-year-old can finally climb a fence with his brother.

Adam: Youre so fast now. Xander: Yeah!

Original post:
Stem Cells Help Md. Boy With Cerebral Palsy To Walk

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported new data from its focal adhesion kinase (FAK) inhibition program and commented on encouraging clinical data on FAK inhibition presented at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland.

Data presented by Verastem in breast cancer models lacking the tumor suppressor Merlin demonstrate that FAK inhibition effectively reduces cancer stem cells in vitro and in vivo. Oral administration of a FAK inhibitor as a single agent was shown to induce tumor regression in a Merlin-negative breast cancer mouse model. These data extend previous research from Verastem, which demonstrated similar inhibition of cancer stem cells and strong single agent efficacy in Merlin-negative mesothelioma models.

Several groups presented data at the conference on the use of FAK inhibitors for treatment of cancer. In one clinical study by GlaxoSmithKline, researchers demonstrated that Merlin loss may identify a subset of patients with improved progression free survival in response to FAK inhibition. These results provide important clinical validation of our internal research demonstrating enhanced sensitivity of Merlin-negative mesothelioma to FAK inhibitors, said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research.

Verastem anticipates initiating a potentially pivotal study in mesothelioma midyear 2013.

The sum of the data on development of FAK inhibitors presented at this conference is very promising, said Professor Dean Fennell, Chair of Thoracic Medical Oncology, University of Leicester. In particular, GSK reported in a Phase 1 trial novel activity of a FAK inhibitor in mesothelioma, where treatment in the second and third-line setting resulted in a median progression free survival of 17.7 weeks.

The largest clinical trial to date in malignant pleural mesothelioma was a 2011 Phase 3 study of Zolinza as a second- and third-line treatment conducted by Merck in 660 patients. In this study, a median progression free survival of only 6 weeks was observed.

Interestingly, loss of the tumor suppressor Merlin correlated with increased clinical sensitivity to FAK inhibition, Prof. Fennell continued. A subset of patients with Merlin negative mesothelioma had more than double the median progression free survival of 24.1 weeks versus 11.4 weeks for the Merlin positive group. These early results suggest that a targeted therapy, particularly when used in combination with a specific biomarker, has the potential to significantly improve treatment of this aggressive and deadly disease.

We are encouraged by the initial clinical data presented today by GSK, said Dr. Joanna Horobin, Verastem Chief Medical Officer. Merlin loss occurs in approximately 50% of mesothelioma patients and we believe that VS-6063 has potential as a targeted therapy in this disease. We are moving rapidly to initiate a potentially pivotal, double blind controlled study next year.

FAK is a cytoplasmic tyrosine kinase that mediates signal transduction by integrins and growth factor receptors. FAK has been implicated in different steps of tumor development including tumor initiation, growth, angiogenesis and metastasis. Verastem has pioneered research on FAK as a critical regulator of cancer stem cells using technology developed by cofounder and chair of the Scientific Advisory Board, Robert Weinberg, Ph.D.

Visit link:
Verastem Reports Data on Focal Adhesion Kinase Program at the 2012 EORTC Symposium on Molecular Targets and Cancer ...

A small study suggests that stem cells from a stranger may be as good as a patient's own in undoing the damage after a heart attack has weakened the heart's ability to pump blood.

Shutterstock

Enlarge photo

A small study suggests that stem cells from a stranger may be as good as a patient's own in undoing the damage after a heart attack has weakened the heart's ability to pump blood. The study hints at the possibility that stem cells could be banked, much like blood is banked, to deal with a medical emergency in this case, heart attack.

The findings on the study of a kind of stem cell called mesenchymal cells were presented at the annual meeting of the American Heart Association this week and published online in the Journal of the American Medical Association.

"We believe the basic message of the study is that this procedure is safe and that future, larger studies are warranted," lead author Dr. Joshua Hare, director of the Interdisciplinary Stem Cell Institute at the University of Miami, told reporters at a national briefing.

The researchers studied patients following heart-attacked-caused ischemic cardiomyopathy, the most common cause of heart failure. According to the Texas Heart Institute, it occurs when the heart suffers a temporary blood shortage, resulting in loss or weakening of heart muscle tissue and reduction in its ability to pump blood.

Whether a donor's cells will work as well is important, because it can take up to two months to grow millions of cells needed for transplant and there's no time in the immediate wake of a heart attack, Stephanie Dimmeler, molecular cardiology section chief at University of Frankfurt in Germany, told U.S. News and World Reports' HealthDay. Dimmeler was not involved in the study.

For the study, researchers looked at 30 patients from Miami who had enlarged hearts that had been damaged by an earlier heart attack. Half received their own mesenchymal stem cells, while the other half received the same kind of cell, but from young, healthy donors. The heart patients each received 20 million, 100 million or 200 million stem cells into 10 scarred left ventricular sites. The researchers then followed their cases for 13 months.

Mesenchymal stem cells are taken from bone marrow and lack a feature on their surface that triggers an immune response called rejection, Hare told the Associated Press. They are multipotent cells that can change to become a number of different types of cells, including bone, muscle, ligament, cartilage, fat and tendon, according to mesenchymalcells.org, which is dedicated to providing information about that particular type of cell. The heart is a muscle tasked with pumping blood throughout the body.

See the rest here:
Study says stem cells — even a stranger's — may repair heart attack damage

ScienceDaily (Nov. 8, 2012) Canadian and Italian stem cell researchers have discovered a new "master control gene" for human blood stem cells and found that manipulating its levels could potentially create a way to expand these cells for clinical use.

The findings, published today online ahead of print in Cell Stem Cell, usher in a new paradigm for the regulation of human blood stem cells, says co-principal investigator Dr. John Dick, who holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network's McEwen Centre for Regenerative Medicine and Ontario Cancer Institute (OCI), the research arm of the Princess Margaret Cancer Centre. He is also a Professor in the Department of Molecular Genetics, University of Toronto.

"For the first time in human blood stem cells, we have established that a new class of non-coding RNA called miRNA represents a new tactic for manipulating these cells, which opens the door to expanding them for therapeutic uses," says Dr. Dick.

In 2011, Dr. Dick isolated a human blood stem cell in its purest form -- as a single stem cell capable of regenerating the entire blood system -- paving the way for clinical uses. He also pioneered the cancer stem cell field by identifying leukemia stem cells in 1994 and colon cancer stem cells in 2007.

OCI lead author Dr. Eric Lechman says the research team removed a master control gene -- microRNA 126 (miR-126) -- that normally governs the expression of hundreds of other genes by keeping them silenced, which in turn keeps the stem cells in a non-dividing dormant state. The method was to introduce excess numbers of miR-126 binding sites into the stem cells by using a specially designed viral vector.

"The virus acted like a sponge and mopped up the specific miRNA in the cells. This enabled the expression of normally repressed genes to become prominent, after which we observed a long-term expansion of the blood stem cells without exhaustion or malignant transformation," says Dr. Lechman.

Adds Dr. Dick: "We've shown that if you remove the miRNA you can expand the stem cells while keeping their identity intact. That's the key to long-term stem cell expansion for use with patients." The co-principal investigator was Dr. Luigi Naldini, Director, of the San Raffaele Telethon Institute for Gene Therapy, Milan.

Dr. Dick's research was funded by the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Foundation, Genome Canada through the Ontario Genomics Institute, the Ontario Institute for Cancer Research, the Canada Research Chair Program, the Ontario Ministry of Health and Long-Term Care, the Canada Foundation of Innovation, as well as The Princess Margaret Cancer Foundation.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

View original post here:
Stem cell scientists discover potential way to expand cells for use with patients

DUBLIN--(BUSINESS WIRE)--

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced multiple presentations of clinical data on its Anti-Notch2/3 and demcizumab programs at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Phase I clinical data on Anti-Notch2/3 were featured in an oral plenary session and additional clinical biomarker data were presented in a poster session. Demcizumab Phase Ib clinical data in non-small cell lung cancer patients were also featured in a separate poster session.

Anti-Notch2/3 (OMP-59R5)

The oral presentation, A First-in-Human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advance Solid Tumors (abstract #28), was presented by Principal Investigator David C. Smith, Professor of Medicine and Urology and the University of Michigan Cancer Center. In the clinical trial (n=39 patients), OMP-59R5 was generally well tolerated, with diarrhea as the main treatment-related and dose-related adverse event. Maximum tolerated doses (MTDs) have been established at doses of 2.5mg/kg weekly and 7.5mg/kg every three weeks. An every two week dosing schedule is also under investigation. Prolonged stable disease was noted in multiple tumor types, including adenoid cystic carcinoma, liposarcoma, Kaposis sarcoma, rectal cancer, and triple-negative breast cancer. Based on these data, OncoMed has advanced Anti-Notch2/3 into an ongoing Phase Ib/II ALPINE trial (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety) in first-line advanced pancreatic cancer patients.

In addition, the company presented a poster (Abstract #314, Poster #64) describing the results of a comprehensive biomarker analysis in the Anti-Notch2/3 Phase 1 study, which demonstrated pharmacodynamic (PD) modulation of the Notch pathway in patients with advanced solid tumors. Principal Investigator Dr. Anthony Tolcher and colleagues of The START Center for Cancer Care, San Antonio, TX concluded that the PD effects of OMP-59R5 on Notch targets, stem cell pathways in surrogate tissues, and in tumor tissue on serial biopsy were clearly established in this first-in-human study at doses equal to or greater than 1mg/kg every other week.

Demcizumab (Anti-DLL4, OMP-21M18)

Interim Phase Ib clinical data in non-small cell lung cancer was presented in a poster session (Abstract #598, Poster #169) at the meeting. Principal Investigator Dr. Mark McKeage of the University of Auckland, Auckland, New Zealand and colleagues reported that in 17 evaluable patients, treatment of demcizumab plus pemetrexed and carboplatin resulted in disease control (partial response plus stable disease by RECIST) in 94% (16 of 17) of patients, including a 44% RECIST partial response rate. Additionally, two patients treated with 5mg/kg every three weeks remain progression free for greater than 16 months. Demcizumab was well tolerated, with fatigue and hypertension being the most common drug-related toxicities. Importantly, no patients experienced significant left ventricular ejection fraction declines or clinical congestive heart failure, which indicates that OncoMeds cardiovascular risk mitigation plan was effective in this trial. Based on this data, OncoMed believes further development of demcizumab in non-small cell lung cancer is warranted.

Both demcizumab and Anti-Notch2/3 appear to have tolerable safety profiles, and we are encouraged by the efficacy and biomarker results to date, noted Jakob Dupont, MD, OncoMeds Chief Medical Officer.

Paul Hastings, President and Chief Executive Officer of OncoMed, added, We are excited to present clinical data on two of our anti-cancer stem cell investigational product candidates at the EORTC-AACR-NCI meeting, and we look forward to advancing both of these product candidates further in clinical development.

About OMP-59R5

View post:
OncoMed Pharmaceuticals Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at EORTC-NCI-AACR Meeting

Integrating History And Philosophy Of Science
ll4.me Integrating History And Philosophy Of Science From the contents: Introduction by Seymour Mauskopf and Tad Schmaltz Part I: General Reflections Thomas Kuhn and Interdisciplinary Conversation: Why Historians and Philosophers of Science Stopped Talking to One Another , Jan Golinski The History and Philosophy of Science History, David M. Miller What in Truth Divides Historians and Philosophers of Science?, Kenneth Caneva History and Philosophy of Science: Recollections and Reflections, Ronald Giere Philosophy of Science and Its Historical Reconstructions , Peter Dear The Underdetermination Debate: How Lack of History Leads to Bad Philosophy, Wolfgang Pietsch Part II: Case Studies Beyond Case Studies: History as Philosophy, Hasok Chang Hidden Entities and Experimental Practice: Renewing the Dialogue between History and Philosophy of Science, Theodore Arabatzis Studying Methodological Thought: S. Weir Mitchell s Research on the Venom of Poisonous Snake, Jutta Schickore Quantum Gravity: History, Historiography and Philosophy, Dean Rickles Social Epistemology of Stem Cell Research: History, Philosophy and Experiment, Melinda Fagan History and Philosophy of Science at Work: Making Regenerative Medicine Better EAN/ISBN : 9789400717459 Publisher(s): Springer, Berlin, Springer Netherlands Discussed keywords: Geschichtsschreibung, Interdisziplinaritt, Wissenschaftsphilosophie Format: ePub/PDF Author(s): Mauskopf, Seymour - Schmaltz, Tad From the contents: Introduction by ...From:susanbranch9865Views:0 0ratingsTime:00:16More inPeople Blogs

Read more:
Integrating History And Philosophy Of Science - Video